Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

September 28, 2017September 28, 2017

Accuray: 93% of Low-risk Prostate Cancer Patients Disease-free 10 Years After CyberKnife Therapy

News

More than 93 percent of men with low risk-prostate cancer treated with the CyberKnife System were still disease-free 10 years later, said the system’s manufacturer, Sunnyvale, California-based Accuray. A study detailing the treatment, “Stereotactic Body ... Read more

September 19, 2017September 19, 2017

Janssen Submits Supplemental New Drug Application for Zytiga to Treat Metastatic Prostate Cancer

News

Janssen Biotech seeks U.S. approval to use a triple combination treatment with Zytiga (abiraterone acetate), prednisone and androgen deprivation therapy (ADT) for men with high-risk metastatic hormone naïve prostate cancer (HNPC) ... Read more

September 6, 2017September 6, 2017

Statin Use Following Prostate Cancer Diagnosis May Reduce Risk of Death, Danish Study Finds

News

Men who began taking statins after being diagnosed with prostate cancer were less like to die than men not on statins, found a Danish study that urged more research ... Read more

July 19, 2017July 19, 2017

Greater Height or Weight Puts Men at Higher Risk for Aggressive Prostate Cancer, Study Finds

News

An analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC) has found that taller men or those with more fat are more likely to develop aggressive forms of ... Read more

June 15, 2017

Compounds in Apples, Grapes and Other Plant Foods Stop Prostate Cancer in Mice, Study Shows

News

Combinations of compounds found in apples, red grapes, berries, turmeric and rosemary stopped prostate cancer cells from growing in the laboratory and also in mice, according to a study. ... Read more

June 9, 2017

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

News

Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did ... Read more

April 20, 2017April 20, 2017

QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies

News

QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and ... Read more

April 4, 2017April 4, 2017

Yervoy Fails to Shut Down Prostate Cancer but Could Be Effective in a Combo Therapy

News

Although the anti-CTLA-4 agent Yervoy (ipilimumab) opens the door to more anti-tumor T-cells entering a prostate-cancer tumor, the treatment produces little patient benefit, a clinical trial indicates. Yerboy activates the ... Read more

March 15, 2017March 15, 2017

Spread of Prostate Cancer Cells to Bone Likely Caused by Enzyme, Mice Study Finds

News

The MAOA enzyme, which is naturally occurring, is a major cause of the spread of prostate cancer cells to the bone, probably by triggering bone degradation, a study in ... Read more

Pin It on Pinterest